<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALBUTEROL <img border="0" src="../images/pr.gif"/></span><br/>(al-byoo'ter-ole)<br/><span class="topboxtradename">Accuneb, </span><span class="topboxtradename">Novosalmol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Proventil, </span><span class="topboxtradename">Proventil HFA, </span><span class="topboxtradename">Proventil Repetabs, </span><span class="topboxtradename">Salbutamol, </span><span class="topboxtradename">Ventolin, </span><span class="topboxtradename">Ventolin HFA, </span><span class="topboxtradename">Volmax<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist (sympathomimetic)</span>; <span class="classification">bronchodilator (respiratory smooth muscle relaxant)</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 4 mg tablets; 4 mg, 8 mg, extended-release tablets;  2 mg/5 mL syrup;  200 mcg capsules for inhalation;  0.083%, 0.5% solution for inhalation</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic sympathomimetic amine and moderately selective beta<sub>2</sub>-adrenergic agonist with comparatively long action. Acts more prominently on beta<sub>2</sub> receptors (particularly smooth muscles of bronchi, uterus, and vascular supply to skeletal muscles) than on beta<sub>1</sub> (heart) receptors. Inhibits histamine release by mast cells. Produces bronchodilation, regardless of administration route,
         by relaxing smooth muscles of bronchial tree.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bronchodilation decreases airway resistance, facilitates mucus drainage, and increases vital capacity.</p>
<h1><a name="uses">Uses</a></h1>
<p>To relieve bronchospasm associated with acute or chronic asthma, bronchitis, or other reversible obstructive airway diseases.
         Also used to prevent exercise-induced bronchospasm.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Adjunct in treatment of refractory heart failure and to stimulate intracellular transport of potassium in hyperkalemic familial
         periodic paralysis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C), lactation. Use of oral syrup in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiovascular disease, hypertension, hyperthyroidism, diabetes mellitus, hypersensitivity to sympathomimetic amines or to
         fluorocarbon propellant used in inhalation aerosols.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Bronchospasm</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 24 mg 34 times/d, 48 mg sustained release 2 times/d <b>Inhaled</b> 12 inhalations q46h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>26 y,</i> 0.10.2 mg/kg t.i.d. (max: 4 mg/dose); <i>612 y,</i> 2 mg 34 times/d <b>Inhaled</b>
<i>612 y,</i> 12 inhalations q46h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not crush extended release tablets. Scored tablets may be broken in half.</li>
<li>
            				Note: An initial dose of 2 mg t.i.d. or q.i.d. is recommended for older adult patients.
            			
         </li>
<li>Store tablets and syrup between 2°25° C (36°77° F) in tight, light-resistant container.</li>
</ul><span class="adminroutetype">Inhalation</span><br/><ul>
<li>Administer albuterol 2030 min before concomitant beclomethasone (Vanceril) inhalation treatments to allow deeper penetration
            of beclomethasone into lungs, unless otherwise directed by physician.
         </li>
<li>Store canisters between 15°30° C (59°86° F) away from heat and direct sunlight.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reaction. <span class="typehead">CNS:</span>
<span class="speceff-common">Tremor,</span> anxiety, nervousness, restlessness, convulsions, weakness, headache, hallucinations. <span class="typehead">CV:</span> Palpitation, hypertension, hypotension, bradycardia, reflex tachycardia. <span class="typehead">Special Senses:</span> Blurred vision, dilated pupils. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Other:</span> Muscle cramps, hoarseness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Transient small increases in <span class="alt">plasma glucose</span> may occur.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> With <b>epinephrine,</b> other <span class="classification">sympathomimetic bronchodilators</span>, possible additive effects; <span class="classification">mao inhibitors</span>, <span class="classification">tricyclic antidepressants</span> potentiate action on vascular system; <span class="classification">beta-adrenergic blockers</span> antagonize the effects of both drugs. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  Inhaled: 515 min; PO 30 min. <span class="typehead">Peak:</span> Inhaled: 0.52 h; PO 2.5 h. <span class="typehead">Duration:</span> Inhaled: 36 h; PO 46 h (812 h with sustained release). <span class="typehead">Metabolism:</span> Metabolized in liver; may cross the placenta. <span class="typehead">Elimination:</span> 76% of dose eliminated in urine in 3 d. <span class="typehead">Half-Life:</span> 2.75 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness which is indicated by significant subjective improvement in pulmonary function within 6090
            min after drug administration.
         </li>
<li>Monitor for: S&amp;S of fine tremor in fingers, which may interfere with precision handwork; CNS stimulation, particularly in
            children 26 y, (hyperactivity, excitement, nervousness, insomnia), tachycardia, GI symptoms. Report promptly to physician.
         </li>
<li>Lab tests: Periodic ABGs, pulmonary functions, and pulse oximetry.</li>
<li>Consult physician about giving last albuterol dose several hours before bedtime, if drug-induced insomnia is a problem.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review directions for correct use of medication and inhaler (see <small>ADMINISTRATION</small>).
         </li>
<li>Avoid contact of inhalation drug with eyes.</li>
<li>Do not increase number or frequency of inhalations without advice of physician.</li>
<li>Notify physician if albuterol fails to provide relief because this can signify worsening of pulmonary function and a reevaluation
            of condition/therapy may be indicated.
         </li>
<li>
            							Note: Albuterol can cause dizziness or vertigo; take necessary precautions.
            						
         </li>
<li>Do not use OTC drugs without physician approval. Many medications (e.g., cold remedies) contain drugs that may intensify albuterol
            action.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>